2018
Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)
Falchi L, Lue J, Montanari F, Marchi E, Amengual J, Sawas A, Deng C, Khan K, Kim H, Atkins L, Rada A, Serge C, O'Connor O. Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL). Blood 2018, 132: 1002. DOI: 10.1182/blood-2018-99-116605.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaAngioimmunoblastic T-cell lymphomaT-cell lymphomaDuration of responseAdverse eventsHypomethylating agentR Peripheral T Cell LymphomaResponse rateMedian DORHigh complete response ratePhase 2Dose-escalation portionG1-2 toxicitiesNausea/vomitingPhase 1 patientsPhase 2 doseComplete response ratePhase 1/2 trialProgression-free survivalOverall response rateTreatment-naïve individualsNon-T-cell lymphomasCancer-testis antigensB-cell lymphomaCombination of AZA
2004
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies
Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Malcovati L, Troletti D, Vanelli L, Varettoni M, Montanari F, Lazzarino M. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplantation 2004, 34: 1039-1045. PMID: 15516936, DOI: 10.1038/sj.bmt.1704717.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBlood TransfusionFemaleGraft SurvivalHematologic NeoplasmsHumansMaleMiddle AgedPeripheral Blood Stem Cell TransplantationRecurrenceRemission InductionSurvival AnalysisThiotepaTransplantation ChimeraTransplantation ConditioningTransplantation, HomologousVidarabineConceptsAllogeneic blood stem cell transplantationPeripheral stem cell transplantBlood stem cell transplantationReduced-intensity conditioning regimenStandard myeloablative regimenTransplant-related mortalityPoor performance statusStem cell transplantStem cell transplantationOverall survival probabilityMyeloablative regimenNonrelapse causesComplete remissionConditioning regimenMild nauseaPreparative regimenAdverse eventsPerformance statusMedian ageRBC transfusionCell transplantCell transplantationHaematological malignanciesSerum amylasePatients